Nanobiotix S.A. - Sponsored ADR

NBTX Healthcare Biotechnology

21.30 0.93 −4.18%
Market cap
$1.1B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
3.40
Beneish M
n/a
Dividend safety
n/a

Nanobiotix S.A. - Sponsored ADR (NBTX) P/E ratio

Alert me on P/E ratio

Nanobiotix S.A. - Sponsored ADR has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period P/E ratio Change
Jun 2021 0.0× —
Dec 2020 0.0× —
Jun 2020 0.0× —
Dec 2019 0.0× —
2 more quarters

Against its own ten years

Low 0.0× High 0.0×
Ten-year median 0.0×
Current reading's percentile 100

P/E ratio against peers

Company P/E ratio
IMTX Immatics N.V. compare n/m
LBRX LB Pharmaceuticals Inc compare n/m
DMRA Galecto, Inc. compare n/m
VOR Vor Biopharma Inc. compare n/m
JANX Janux Therapeutics, Inc. compare n/m
BCAX Bicara Therapeutics Inc. compare n/m
DRTS Alpha Tau Medical Ltd. compare n/m
NBTX Nanobiotix S.A. - Sponsored ADR n/m
REPL Replimune Group, Inc. compare n/m
Biotechnology industry median 8.5×
Healthcare sector median 23.0×
Market median 18.1×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on NBTX